The FT puts the price for PCYC at a total of $19bn which would leave some room for further appreciation. If that came from the Daily Mail I'd dismiss it, but the FT deserves some respect.
Pharmacyclics is considering a sale that could value the US cancer drugs maker at about $19bn, according to people familiar with the matter, suggesting that consolidation in the pharmaceutical industry is far from over.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.